BiotechTube
Home/Kalbe/Dr. R. H. Siregar
DR

Dr. R. H. Siregar

Chief Scientific Officer

Kalbe

Therapeutic Areas

OncologyImmunologyCardiovascularMetabolismInfectious Diseases

Kalbe Pipeline

DrugIndicationPhase
K‑001Non‑small cell lung cancerPhase 3
K‑202Rheumatoid arthritisPhase 2
K‑303Various solid tumors (bevacizumab biosimilar)Phase 3

Leadership Team at Kalbe

DH
Dr. Hary Tanoesoedibjo
President Director & CEO
View full Kalbe profile